secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001104659-26-005038
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura receives $300K loans from controlling shareholder; warns of potential shutdown if no funding by Jan 2026
--------------------------------------------------------------------------------

- On Dec 31, Jan 2, and Jan 16, 2026, Acura received $100K each from Abuse Deterrent Pharma (65% owner), bringing note principal to $9.59M.
- Note bears 5.25% interest; default rate 7.5%; events of default include bankruptcy and failure to pay within 5 days.
- Company states that without additional financing by end of January 2026, it will scale back operations or seek bankruptcy protection.
- AD Pharma holds ~65% of Acura's common stock; entity controlled by Mr. Schutte, who directly owns ~13%.
- Proceeds fund day-to-day operations; company warns of potential complete loss of shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/0001104659-26-005038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926005038/tm263622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-005038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer